Showa University Reports Findings in Information Technology [Risk Factors for Thromboembolic and Bleeding Events in Patients After the Fontan Operation (Insights from the National Database of Health Insurance Claims of Japan)]: Information Technology

Insurance Daily News

2023 NOV 22 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Information Technology is the subject of a report. According to news reporting originating in Tokyo, Japan, by NewsRx journalists, research stated, “Risk stratification of thromboembolic events (TEs) and bleeding events is important for the appropriate selection of thromboprophylaxis in patients after the Fontan operation. Therefore, we clarified the risk factors for TEs and bleeding events in patients after the Fontan operation using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.”

The news reporters obtained a quote from the research from Showa University, “We conducted a retrospective cohort study including 2,515 patients who underwent the Fontan operation between June 2011 and September 2019. The end points were TEs and bleeding events within 1 year of the Fontan operation analysis. We analyzed the risk factors for these end points using a multivariate analysis. In total, 1,903 patients were included in the analysis. The median age at the time of the Fontan operation was 3 (1 to 22) years, and 1,067 patients (56%) were male. The incidence rates of TEs and bleeding events were 12% and 11%, respectively. Age (odds ratio [OR] 1.1 per 1 year older, p<0.05) was an independent risk factor for TEs. Thromboprophylaxis with aspirin after the Fontan operation significantly reduced TEs (OR 0.3, p<0.05). A history of postoperative hemorrhage (OR 1.5, p<0.05) and the use of a potassium channel blocker (OR 2.1, p<0.05) were independent risk factors for bleeding events.”

According to the news reporters, the research concluded: “Aspirin was found to reduce the risk of TEs within 1 year of the Fontan operation. The results of this study will be useful in selecting effective and safe thromboprophylaxis in patients after the Fontan operation.”

This research has been peer-reviewed.

For more information on this research see: Risk Factors for Thromboembolic and Bleeding Events in Patients After the Fontan Operation (Insights from the National Database of Health Insurance Claims of Japan). The American Journal of Cardiology, 2023;207:399-406. The American Journal of Cardiology can be contacted at: Excerpta Medica Inc-elsevier Science Inc, 685 Route 202-206 Ste 3, Bridgewater, NJ 08807, USA.

Our news correspondents report that additional information may be obtained by contacting Masayoshi Hosoi, Division of Pharmacotherapeutics, Dept. of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan. Additional authors for this research include Masayuki Ohbayashi, Yoshinori Miyahara, Takanari Fujii, Hiroaki Kise and Mari Kogo.

The publisher of the The American Journal of Cardiology can be contacted at: Excerpta Medica Inc-elsevier Science Inc, 685 Route 202-206 Ste 3, Bridgewater, NJ 08807, USA.